Your browser doesn't support javascript.
loading
EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).
Ruiz-Patiño, Alejandro; Castro, Christian David; Ricaurte, Luisa María; Cardona, Andrés F; Rojas, Leonardo; Zatarain-Barrón, Zyanya Lucia; Wills, Beatriz; Reguart, Noemí; Carranza, Hernán; Vargas, Carlos; Otero, Jorge; Corrales, Luis; Martín, Claudio; Archila, Pilar; Rodriguez, July; Avila, Jenny; Bravo, Melissa; Pino, Luis Eduardo; Rosell, Rafael; Arrieta, Oscar.
Afiliação
  • Ruiz-Patiño A; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.
  • Castro CD; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.
  • Ricaurte LM; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.
  • Cardona AF; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia. andres.cardona@clinicadelcountry.com.
  • Rojas L; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia. andres.cardona@clinicadelcountry.com.
  • Zatarain-Barrón ZL; Molecular Oncology and Biology Systems Research Group (FOX-G), Universidad El Bosque, Bogotá, Colombia. andres.cardona@clinicadelcountry.com.
  • Wills B; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
  • Reguart N; Clinical Oncology Department, Clínica Colsanitas, Bogotá, Colombia.
  • Carranza H; Thoracic Oncology Unit and Laboratory of Personalized Medicine, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
  • Vargas C; Internal Medicine Department, Johns Hopkins University, Baltimore, MD, USA.
  • Otero J; Medical Oncology Department, Hospital Clinic, Barcelona, Spain.
  • Corrales L; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.
  • Martín C; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
  • Archila P; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.
  • Rodriguez J; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
  • Avila J; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.
  • Bravo M; Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogotá, Colombia.
  • Pino LE; Clinical Oncology Department, Hospital San Juan de Dios, San José, Costa Rica.
  • Rosell R; Thoracic Oncology Unit, Alexander Fleming Institute, Buenos Aires, Argentina.
  • Arrieta O; Foundation for Clinical and Applied Cancer Research (FICMAC), Calle 116 No. 9-72, c. 318, Bogotá, Colombia.
Target Oncol ; 13(5): 621-629, 2018 10.
Article em En | MEDLINE | ID: mdl-30284706
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cloridrato de Erlotinib / Adenocarcinoma de Pulmão / Neoplasias Pulmonares / Mutação / Antineoplásicos Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Target Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Colômbia País de publicação: França
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cloridrato de Erlotinib / Adenocarcinoma de Pulmão / Neoplasias Pulmonares / Mutação / Antineoplásicos Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Target Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Colômbia País de publicação: França